花旗研究报告指,锦欣生殖(01951.HK) 上半年收入12.88亿元人民币(下同),按年下降10.7%,净亏损10.44亿元。管理层指业绩疲弱因初诊患者减少及宫腔内人工授精(IUI)比例上升导致试管婴儿周期数下降、保险覆盖后每个周期的平均售价下降7%至8%、生育意愿降低导致产科收入减少,以及海外业务相关减值损失。展望未来,管理层正寻求分拆HRC业务,并将焦点重新转回中国内地市场;预计2026...
Source Link花旗研究报告指,锦欣生殖(01951.HK) 上半年收入12.88亿元人民币(下同),按年下降10.7%,净亏损10.44亿元。管理层指业绩疲弱因初诊患者减少及宫腔内人工授精(IUI)比例上升导致试管婴儿周期数下降、保险覆盖后每个周期的平均售价下降7%至8%、生育意愿降低导致产科收入减少,以及海外业务相关减值损失。展望未来,管理层正寻求分拆HRC业务,并将焦点重新转回中国内地市场;预计2026...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.